MARKET

ATOS

ATOS

Atossa Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.480
-0.100
-6.33%
After Hours: 1.490 +0.01 +0.68% 17:39 04/09 EDT
OPEN
1.640
PREV CLOSE
1.580
HIGH
1.650
LOW
1.450
VOLUME
258.30K
TURNOVER
--
52 WEEK HIGH
4.260
52 WEEK LOW
0.7550
MARKET CAP
13.51M
P/E (TTM)
-0.7175
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ATOS stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.

EPS

ATOS News

More
  • W, IMMU, LK and BPT among midday movers
  • Seeking Alpha - Article · 4d ago
  • Atossa Therapeutics Announces Clinical Progress
  • GlobeNewswire · 04/02 13:00
  • New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients
  • GlobeNewswire · 03/30 13:00
  • Atossa Genetics EPS in-line
  • seekingalpha · 03/26 17:06

Industry

Biotechnology & Medical Research
+1.63%
Pharmaceuticals & Medical Research
+0.82%

Hot Stocks

Symbol
Price
%Change

About ATOS

Atossa Therapeutics Inc., formerly Atossa Genetics Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics and delivery methods for breast cancer and other breast conditions. Its pipeline includes two programs: endoxifen and intraductal microcatheter technology. It is developing Topical Endoxifen formulation for transdermal delivery. It is developing Topical Endoxifen to address two populations: to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy. It is also developing oral presentation of endoxifen. It is developing its microcatheter technology to deliver therapeutics through the nipple directly to the site of early breast cancer. It is also developing our proprietary intraductal microcatheter technology for Chimeric Antigen Receptor Therapy (CAR-T).
More

Webull offers kinds of Atossa Therapeutics Inc stock information, including NASDAQ:ATOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATOS stock news, and many more online research tools to help you make informed decisions.